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Clinics and pathology 
Disease 
Myeloproliferative neoplasm with essential 
thrombocythemia 
Note 
No detectable BCR-ABL transcript or JAK2 V617F 
mutation. 
Epidemiology 
Found in one case of myeloproliferative neoplasm 
with severe thrombocythemia, in a 67-year-old male. 
Clinics 
Thrombocythemia (platelets, 904 x 109/l) without 
prominent eosinophilia or neutrophilia. 
Cytology 
Increased number of polymorphic megakaryocytes 
without any blast cells or dysplastic features; 
suggestive of myeloproliferative neoplasm, most 
likely essential thrombocythemia. 
Treatment 
No response to hydroxyurea, complete remission with 
imatinib at the dose of 100 mg/day. 
Evolution 








Disruption of PDGFRβ (5q31~32) and KANK1 
(9p24.3) loci. 
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FISH analysis using the RP11-130C19 and RP11-31F19 probes. RP11-130C19 is split between the der(5) and the der(9), while 
RP11-31F19 is translocated to the der(5). 
 
Probes 
RP11-130C19 and RP11-31F19. 
Additional anomalies 
No. 
Genes involved and 
proteins 





Formerly: KANK, ANKRD15, KIAA0172. 
Protein 
Two KANK1 protein isoforms are encoded by 
different transcripts of the same gene: a long isoform 
of 1352 amino-acids and a short one 1194 aa, which 
is predominant in hematopoietic cells (Medves et al., 
2010).  
Both isoforms have multiple N-terminal coiled-coil 
domains, which are included in the fusion with 
PDGFRB, and C-terminal ankyrin repeat domains 
(Kakinuma et al., 2009). 
PDGFRB (platelet-derived growth 




Platelet-derived growth factors (PDGF) receptor, beta 
isoform. This receptor belongs to the receptor 
tyrosine kinase family (type III). 




Exon 2 of KANK1 (ENST00000382293, Ensembl 
database, up to nucleotide 3020) is fused to exon 9 of 




The fusion protein contains the first 741 residues of 
KANK1 fused to the last 692 residues of PDGFRB 
(Medves et al., 2010). This includes several coiled-
coil domains of KANK1 and the fifth 
immunoglobulin-like domain, the transmembrane 
domain and the kinase domain of PDGFRB. The 
deletion of the immunoglobulin-like domain does not 
affect the oncogenic activity of the fusion (Medves et 
al., 2010). By contrast, deletion of the coiled-coil 
domains prevents cell transformation and signaling 
via STAT5 and MAP kinases (Medves et al., 2011). 
Our data suggest that KANK1-PDGFRB adopts a 
trimeric and multimeric conformation (Medves et al., 
2011). 
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Structure of PDGFRB, KANK1 and the KANK1-PDGFRB fusion. See text for details. KOD, KANK1 oligomerization domain. Adapted 
from Demoulin et al., 2012 and Medves et al., 2012. 
 
Oncogenesis 
This fusion protein induces the proliferation of Ba/F3 
cells (Medves et al., 2010) and CD34+ human 
progenitors (Medves et al., 2011). 
The fusion was identified in thrombocythemia, which 
is associated with JAK2 mutations or indirect 
activation of JAK2 by mutated thrombopoietin 
receptors (c-MPL).  
In the present case, no JAK2 activation was detected 
in cells expressing KANK1-PDGFRB and these cells 
are not sensitive to JAK inhibitors (Medves et al., 
2011).  
Instead, they are highly sensitive to imatinib. 
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